Nektar completes enrollment in REZOLVE-AD Phase 2b study of rezpegaldesleukin

Nektar (NKTR) Therapeutics announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. “We are pleased to announce that we reached our target enrollment for our 396-patient Phase 2b trial of rezpegaldesleukin,” said Howard Robin, President and CEO of Nektar Therapeutics. “We are grateful to the patients and physicians whose strong interest in this novel mechanism, together with the proof-of-concept clinical data, led to completing enrollment of the study in just 14 months. Less than 10% of the 30 million atopic dermatitis patients who can receive biologics in the US and Europe are currently receiving treatment and we believe that novel mechanisms are key to helping more patients with this chronic and serious skin disorder. We look forward to announcing the topline data from the 16-week induction treatment period in this study in the second quarter of 2025.”